Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Fludarabine, Mitoxantrone, and Rituximab in Follicular Lymphoma
NCT01560117Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Jan 2004
- Primary completion
- Jul 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rituximab in follicular lymphoma (FL), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Conversion rate of bcl-2 in blood and bone marrow defined by PCR at 3 years. Started Jan 2004; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01560117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01560117.